The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
Open accessAbstract
A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87% of metastases. AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/AR-V7 double-positive metastases were found in 77% of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T. M., Luo, B., Grenier, J. K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.040 · Cited by 1,798
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Fu, S., Yang, L., Li, P., Hofmann, O., Dicker, L., Hide, W., Lin, X., Watkins, S. M., Ivanov, A. R., & Hotamisligil, G. S. (2011) · Nature · doi:10.1038/nature09968 · Cited by 1,020
The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages
Feng, B., Yao, P. M., Li, Y., Devlin, C. M., Zhang, D., Harding, H. P., Sweeney, M., Rong, J. X., Kuriakose, G., Fisher, E. A., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb1035 · Cited by 885
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Self-citationA possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis.
McGarry, J. D., Mannaerts, G. P., & Foster, D. W. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108764 · Cited by 736
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
Self-citationHu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Self-citationHörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 498
Ventura, R., Mordec, K., Waszczuk, J., Wang, Z., Lai, J., Fridlib, M., Buckley, D., Kemble, G., & Heuer, T. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.020 · Cited by 301
Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.
Rossi, S., Graner, E., Febbo, P. G., Weinstein, L. J., Bhattacharya, N., Ónody, T., Bubley, G. J., Balk, S. P., & Loda, M. F. (2003) · PubMed · Cited by 301
Self-citationThe fat side of prostate cancer
Zadra, G., Photopoulos, C., & Loda, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.03.010 · Cited by 291
Self-citationEttinger, S. L., Sobel, R., Whitmore, T. G., Akbari, M., Bradley, D. R., Gleave, M. E., & Nelson, C. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2148-2 · Cited by 287
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
Lipid-dependent regulation of the unfolded protein response
Volmer, R., & Ron, D. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.12.002 · Cited by 241
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., Vakar-Lopez, F., Vessella, R. L., & Plymate, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027970 · Cited by 240
Self-citationMyc confers androgen-independent prostate cancer cell growth
Bernard, D., Pourtier, A., Gil, J., & Beach, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19035 · Cited by 224
Chan, S. C., Li, Y., & Dehm, S. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.352930 · Cited by 218
Self-citationA novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis
Zadra, G., Photopoulos, C., Tyekucheva, S., Heidari, P., Weng, Q. P., Fedele, G., Liu, H., Scaglia, N., Priolo, C., Sicinska, E., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302734 · Cited by 204
Self-citationBreitkopf, S. B., Ricoult, S. J. H., Yuan, M., Xu, Y., Peake, D. A., Manning, B. D., & Asara, J. M. (2017) · Metabolomics · doi:10.1007/s11306-016-1157-8 · Cited by 192
Paller, C. J., & Antonarakis, E. S. (2013) · PubMed · Cited by 186
Li, X., Chen, Y.-T., Hu, P., & Huang, W.-C. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0797 · Cited by 184
Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells
Little, J. L., Wheeler, F. B., Fels, D. R., Koumenis, C., & Kridel, S. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1794 · Cited by 181
Kohli, M., Ho, Y., Hillman, D. W., Etten, J. L. V., Henzler, C. M., Yang, R., Sperger, J. M., Li, Y., Tseng, E., Hon, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0017 · Cited by 166
Self-citationWatson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., LeBeau, M. M., & Sawyers, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3441 · Cited by 159
Alwarawrah, Y., Hughes, P. F., Loiselle, D. R., Carlson, D. A., Darr, D. B., Jordan, J. L., Xiong, J., Hunter, L., Dubois, L. G., Thompson, J. W., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.04.011 · Cited by 159
Chan, S. C., Selth, L. A., Li, Y., Nyquist, M. D., Lu, M., Bradner, J. E., Raj, G. V., Tilley, W. D., & Dehm, S. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv262 · Cited by 158
Self-citationDiverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Chen, Z., Wu, D., Thomas-Ahner, J. M., Lu, C., Zhao, P., Zhang, Q., Geraghty, C., Yan, P. S., Hankey, W., Sunkel, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718811115 · Cited by 158
Sadowski, M. C., Pouwer, R. H., Gunter, J. H., Lubik, A. A., Quinn, R. J., & Nelson, C. C. (2014) · Oncotarget · doi:10.18632/oncotarget.2433 · Cited by 156
Swinnen, J. V., Veldhoven, P. P. V., Esquenet, M., Heyns, W., & Verhoeven, G. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828509 · Cited by 154
AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer
Priolo, C., Pyne, S., Rose, J. A., Regan, E. R., Zadra, G., Photopoulos, C., Cacciatore, S., Schultz, D., Scaglia, N., McDunn, J. E., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1490 · Cited by 143
Self-citationAndrogen Activation of the Sterol Regulatory Element-Binding Protein Pathway: Current Insights
Heemers, H. V., Verhoeven, G., & Swinnen, J. V. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0479 · Cited by 139
Heuer, T. S., Ventura, R., Mordec, K., Lai, J., Fridlib, M., Buckley, D., & Kemble, G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.012 · Cited by 136 · cited 1×
“Therefore, FASN may be targeted in the majority of mCRPC, regardless of AR-V7 status (43).”
BackgroundAndrogen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
Gao, L., Schwartzman, J. A., Gibbs, A., Lisac, R., Kleinschmidt, R., Wilmot, B., Bottomly, D., Coleman, I. M., Nelson, P. S., McWeeney, S. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063563 · Cited by 133
Nadiminty, N., Tummala, R., Liu, C., Lou, W., Evans, C. P., & Gao, A. C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1057 · Cited by 132
Welti, J. C., Rodrigues, D. N., Sharp, A., Sun, S., Lorente, D., Riisnaes, R., Figueiredo, I., Zafeiriou, Z., Rescigno, P., Bono, J. S. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.03.049 · Cited by 132
Self-citationWu, X., Dong, Z., Wang, C. J., Barlow, L., Fako, V. E., Serrano, M. A., Zou, Y., Liu, J., & Zhang, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609934113 · Cited by 105
Fatty acid synthase inhibitors: new directions for oncology
Kridel, S. J., Lowther, W. T., & Pemble, C. W., IV (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.11.1817 · Cited by 98
De novo fatty acid synthesis at the mitotic exit is required to complete cellular division
Scaglia, N., Tyekucheva, S., Zadra, G., Photopoulos, C., & Loda, M. F. (2014) · Cell Cycle · doi:10.4161/cc.27767 · Cited by 96
Self-citationYokomizo, A., Shiota, M., Kashiwagi, E., Kuroiwa, K., Tatsugami, K., Inokuchi, J., Takeuchi, A., & Naito, S. (2010) · The Prostate · doi:10.1002/pros.21243 · Cited by 51
Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth
Fritz, V., Benfodda, Z., Henriquet, C., Huré, S., Cristol, J., Michel, F., Carbonneau, M.-A., Casas, F., & Lluis Fajas, A. (2012) · Oncogene · doi:10.1038/onc.2012.523 · Cited by 44
Griend, D. J. V., Antony, L., Dalrymple, S. L., Xu, Y., Christensen, S. B., Denmeade, S. R., & Isaacs, J. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1136 · Cited by 43
Brenner, A., Falchook, G., Patel, M., Infante, Jr., Arkenau, H.-T., Dean, E., Borazanci, E., Lopez, J., Moore, K., Schmid, P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-p6-11-09 · Cited by 19
Abstract 3457: Galectin-1 suppression enhances combined anti-EGFR and radiation-therapy of NSCLC
Siedow, M. R., Chakravarti, A., & Lautenschlaeger, T. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3457 · Cited by 13
Patel, M. R., Infante, J. R., Hoff, D. D. V., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct203 · Cited by 12
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Self-citationLipogenesis inhibitors: therapeutic opportunities and challenges
Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00367-2 · Cited by 399
Tumour fatty acid metabolism in the context of therapy resistance and obesity
Hoy, A. J., Nagarajan, S. R., & Butler, L. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00388-4 · Cited by 392
Self-citationMetabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 328
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 266
Metadata
- Authors
- Zadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., Syamala, S., Bango, C., Photopoulos, C., Huang, Y., Tyekucheva, S., Bastos, D. C., Tchaicha, J., Lawney, B., Uo, T., D’Anello, L., Csibi, A., Kalekar, R., Larimer, B., Ellis, L., Butler, L. M., Morrissey, C., McGovern, K., Palombella, V. J., Kutok, J. L., Mahmood, U., Bosari, S., Adams, J., Peluso, S., Dehm, S. M., Plymate, S. R., & Loda, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-12-21
- Volume
- 116
- Issue
- 2
- Pages
- 631-640
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2905917937
- Cited by
- 291
- References
- 53
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.